Kyle Donahue, who was given months to live after receiving a diagnosis of glioblastoma in 2021, enrolled in a clinical trial ...
The trial used CAN-3110, an engineered herpes virus, to target and kill glioblastoma tumor cells. CURE sat down with Dr. E.
Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free ...
Rising incidence rates, high recurrence, and limited curative options are accelerating demand for innovative glioblastoma ...
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to ...
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...
Glioblastoma is the most aggressive and lethal form of primary brain cancer in adults. Experts explain why it spreads so ...
UP Oncolytics has been given an Illinois Innovation Voucher grant to further work on a novel treatment for glioblastoma ...
Glioblastoma (GBM) is one of the most common and aggressive primary brain tumors in adults, carrying an extremely poor ...
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback